Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

Long-term use of many common cardiovascular drugs was tied to fewer dementia diagnoses but anti-platelet use of any duration ...

There's no cure for this disease, but now there is some hope for people and their families who are battling the illness in ...

An experimental nasal spray has helped clear toxic protein buildups in the brains of mouse models of Alzheimer's. Its ...

Today, Haldi is traveling, finishing puzzles, dancing and playing trombone in the Project Joy Orchestra. Turning 85 next ...

Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...

Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new study. Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to ...

Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing ...